MedTrace Logo

Image Quality and Radiation Dose in Angiography

NCT01381952 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2014-05-22

Study results available
· View outcomes & findings →

Summary

ClarityIQ is a novel X-ray imaging technology, that combines advanced real-time image noise reduction algorithms, with state-of-the-art hardware to reduce patient entrance dose significantly. This is realized by anatomy-specific optimization of the full acquisition chain (grid switch, beam filtering, pulse width, spot size, detector and image processing engine) for every clinical task individually. Furthermore, smaller focal spot sizes and shorter pulses are used, which are known to positively influence image quality . The final effect on the clinical image quality is investigated in this study.

Conditions

  • Arteriovenous Malformations
  • Aneurysm
  • Stenosis
  • Dural Arteriovenous Malformations

Interventions

RADIATION

Low dose DSA (75% reduction compared to normal dose) with novel X-ray imaging technology.

Digital substraction angiography (DSA) with reduced dose settings (75% reduction expected) in combination with conventional X-ray imaging technology.

RADIATION

Normal dose DSA with conventional X-ray technology

Digital substraction angiography (DSA) with normal dose settings in combination with conventional X-ray imaging technology.

Sponsors & Collaborators

  • Philips Medical Systems

    collaborator INDUSTRY

  • Karolinska University Hospital

    lead OTHER

Principal Investigators

  • Michael Söderman, MD, PhD · Karolinska University Hospital

  • Tommy Andersson, MD, PhD · Karolinska University Hospital

  • Staffan Holmin, MD, PhD · Karolinska University Hospital

Study Design

Allocation
NON_RANDOMIZED
Purpose
DIAGNOSTIC
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-06-30
Primary Completion
2011-08-31
Completion
2011-09-30

Countries

  • Sweden

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01381952 on ClinicalTrials.gov